Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group.
30 patients with advanced ovarian cancer, all platinum pretreated, were treated with an induction cycle of fotemustine. Maintenance therapy was given to 6 patients. No objective response was observed among the 21 evaluable patients. The main toxicities were gastrointestinal, with grade 3 nausea and vomiting reported in 40% of the patients, and haematological, with grade 4 leucopenia reported in 2 patients and grade 4 thrombocytopenia in 5 patients. Therefore, no role has been demonstrated in our cohort for the use of fotemustine, a nitrosourea, in pretreated ovarian cancer.
Aapro
M S
MS
Division of Medical Oncology, Clinique de Genolier, Geneva 1272, Switzerland. aapro@cdg.ch
van Wijk
F H
FH
van der Burg
M E L
ME
ten Bokkel Huinink
W
W
Vergote
I
I
Guastalla
J P
JP
Rosso
R
R
Kobierska
A
A
Beex
L V A
LV
Namer
M
M
Splinter
T E W
TE
Vermorken
J B
JB
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009607:Nitrosourea Compounds / Q000008:administration & dosage*; D009943:Organophosphorus Compounds / Q000008:administration & dosage*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; C054368:fotemustine